Cara Therapeutics CARA

$5.32 -0.23 (-4.14%)

Valuation

Market cap
24,332,000
Revenue TTM
$7,140,000
Net income TTM
$-70,870,000
PE ratio
0.00
Forward PE
—
Profit margin
-992.58%
Debt to equity
0.00

Trading

Volume
237,100
Avg volume
21,144
Day's range
$5.28 – $5.52
Shares out
4,574,000
Stochastic %K
65%
Beta
0.41
Analysts
Strong Sell
Price target
$96.04

Price

Company profile

Cara Therapeutics, Inc. operates as a biopharmaceutical company that focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Ph...

Show more

Cara Therapeutics, Inc. operates as a biopharmaceutical company that focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Industry
Biotechnology
Sector
Healthcare
Phone
(203) 406-3700
Website
https://www.caratherapeutics.com
Address
400 Atlantic Street, Suite 500, Stamford, United States

Latest news

Stocktwits

StocktwitsEarnings Aug 14, 6:00 PM
$CARA Q2 '26 Earnings Results & Recap Reported GAAP EPS of -$0.69 down -235.29% YoY
0 replies
iamyahweh Jul 1, 3:41 PM
$CARA 🚀🚀🚀🚀🦓
0 replies
Bigprofits23 Jun 24, 1:16 PM
$CARA is this even a company anymore? Did it go bankrupt? So glad I got out 5 years ago when it touched the $20’s. Yes, it’s true, even a blind squirrel finds a nut once in a while!
0 replies
liadanielle Feb 10, 9:29 PM
$CARA FBIO!!!! Hold this long and make your money back
0 replies
liadanielle Feb 10, 9:20 PM
$CARA Wow!! I made a lot of money on this stock 3 to 4 years ago buying and selling up and down. They had revolutionary ideas. But I guess they’re shit just don’t work.
0 replies
Buckwacker Jan 3, 1:54 AM
$CARA this is down 540 percent in five years I lost 16 k They suck…
0 replies
Buckwacker Dec 15, 8:18 PM
$CARA wholly shit!! I haven’t looked at this for a bout a year Reverse split horror show…. 🤦🏻‍♂️
0 replies
saudq1978 Oct 22, 4:59 PM
$CARA
0 replies